Diagenode

Founded in 2003 and headquartered in Liège, Belgium, Diagenode has established itself as a key technology enabler in the epigenomics and genomics research space, renowned for its Bioruptor® shearing systems. Its strategic acquisition by Hologic in 2021 has transformed its trajectory, embedding it within a larger diagnostics powerhouse to accelerate commercial reach and R&D synergies. The company's mission is to drive groundbreaking innovations in epigenomics to empower healthier lives, supported by a dual-pillar strategy of proprietary sample preparation products and high-value epigenomics profiling services.

Centered on sample preparation and analysis for epigenomics and genomics, featuring flagship ultrasonic shearing instruments (Bioruptor®, Megaruptor®), automation systems (IP-Star®), and a comprehensive suite of optimized reagents, antibodies, and assay kits for chromatin studies and DNA methylation.

Competes in specialized segments against companies like Covaris (shearing), Active Motif and Abcam (reagents/antibodies), and large CROs (services). Its advantages are deep epigenetics specialization, an integrated platform, and the powerful commercial and clinical channel of its parent company, Hologic.